Brain and spinal cord tumours have unique characteristics which, up until now, have required some samples to be sent overseas for methylation profiling testing. Building on the success of the Molecular NeuroPathology (MNP 2.0) study, AIM-BRAIN will enable rapid and accurate analysis and diagnosis of brain and spinal cord tumours to be done in Australia. More accurate information about each child or adolescent’s tumour will help doctors decide which treatment is best, and help create targeted treatments. AIM-BRAIN is now being rolled out across Australia and New Zealand and will ensure all Australian and New Zealand children are able to access the best diagnostic testing now and in the future.
Disease Stage: Newly diagnosed and relapsed suspected primary CNS tumours
Patient Age Range: Children and adolescents (<21 years of age)
Sample Size: ~ 400
- National: ANZCHOG